Evaluation report: immunochemical faecal occult blood tests
The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions. Summary: Immunological faecal occult blood tests (iFOBT) use antibodies rasied against human haemoglobin (Hb) to detect human blood present in faeces. The presence of blood in a faecal sample can be used as a marker to detect significant neoplasia in otherwise asymptomatic people. They have the potentially to be used in bowel cancer screening programmes. This document is an assessment of the perfomance of three automated analytical iFOB methods. Publication history information: Published in November 2009. Access: Available to the general public. (Source: Gastroenterology and Liver Diseases Specialist Library......
POSTED 02/25/2010 at 07:12 AM --
|
Clinical Trial Launched To Test New Treatment Technique For Bowel Cancer
Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy. Researchers at trial centres across the UK and coordinated at Oxford University will test a new treatment called Radio-embolisation, a form of internal radiotherapy that uses the tumour's blood supply to target multiple sites of disease within the liver... (Source: Health News from Medical News Today)...
POSTED 02/25/2010 at 07:00 AM --
|
Clinical Trial Launched To Test New Treatment Technique For Bowel Cancer
Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy... (Source: Cancer / Oncology News From Medical News Today)...
POSTED 02/25/2010 at 07:00 AM --
|
Evaluation report: immunochemical faecal occult blood tests
The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions. Summary: Immunological faecal occult blood tests (iFOBT) use antibodies rasied against human haemoglobin (Hb) to detect human blood present in faeces. The presence of blood in a faecal sample can be used as a marker to detect significant neoplasia in otherwise asymptomatic people. They have the potentially to be used in bowel cancer screening programmes. This document is an assessment of the perfomance of three automated analytical iFOB methods. Publication history information: Published in November 2009. Access: Available to the general public. (Source: Gastroenterology and Liver Diseases Specialist Library......
POSTED 02/24/2010 at 06:48 AM --
|
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Conclusions Treatment with flavopiridol and FOLFIRI is a safe and effective regimen. Concentrations of flavopiridol that enhance the effects
of FOLFIRI can be achieved. Clinical activity is encouraging and includes prolonged stable disease in patients with irinotecan-refractory
colorectal cancer.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1269-1Authors
Mark A. Dickson, Memorial Sloan-Kettering Cancer Center Melanoma and Sarcoma Service, Department of Medicine 1275 York Avenue New York NY 10065 USAManish A. Shah, Memorial Sloan-Kettering Cancer Center Gastrointestinal Oncology Service, Department of Medicine New York NY USADana Rathkopf, Memorial Sloan-Kettering Cancer Center Genitourinary Oncology Service New York NY USAArchie Tse, M......
POSTED 02/21/2010 at 12:54 AM --
|
Cancer's genetic fingerprint could personalise treatments
Personalised blood tests will mean doctors can monitor how well a particular patient's cancer is responding to surgery or therapyA personalised blood test that monitors cancer in the body and spots when it has returned after treatment has been developed by scientists.Researchers believe the test will give doctors a way to tailor cancer treatments to individual patients by monitoring how well their tumour has responded to surgery or therapy and picking up the early signs of a recurrence.In principle, the test could be used to keep watch over any kind of cancer that scientists can collect cells from.Scientists developed the test after deciphering the full genomes of tumour tissue taken from six patients. Most cancers contain large-scale rearrangements of genetic material that aren't seen in ......
POSTED 02/18/2010 at 12:59 PM --
|
Cancer's genetic fingerprint to personalise treatment
Personalised blood tests will mean doctors can monitor how well a particular patient's cancer is responding to surgery or therapyA personalised blood test that monitors cancer in the body and spots when it has returned after treatment has been developed by scientists.Researchers believe the test will give doctors a way to tailor cancer treatments to individual patients by monitoring how well their tumour has responded to surgery or therapy and picking up the early signs of a recurrence.In principle, the test could be used to keep watch over any kind of cancer that scientists can collect cells from.Scientists developed the test after deciphering the full genomes of tumour tissue taken from six patients. Most cancers contain large-scale rearrangements of genetic material that aren't seen in ......
POSTED 02/18/2010 at 12:59 PM --
|
Genetic 'Hotspots' Flag Up Opportunities For More Personal Bowel Cancer Treatment
Cancer Research UK scientists have identified the frequency of new genetic 'hotspots' which could help doctors to tailor therapies to as many as 3,000 additional bowel cancer patients each year, according to research published in the British Journal of Cancer today. The team at the University of Dundee carried out a genetic analysis on 106 bowel cancer tumour samples to search for the frequency of known faults in a key gene called K-Ras. This gene is the blueprint for an important protein which acts as an 'on-off switch' in cells to control growth... (Source: Health News from Medical News Today)...
POSTED 02/12/2010 at 05:00 AM --
|
COPD awareness
Chronic obstructive pulmonary disease is the UK’s fifth biggest killer, each year causing more deaths than breast, prostate and bowel cancer. However, 2.8 million people are undiagnosed and unaware they have the progressive, possibly terminal disease. (Source: HSJ)...
POSTED 02/11/2010 at 10:03 AM --
|
Bowel cancer therapy breakthrough
The era of personalised cancer treatment has moved a step closer after a new genetic study by UK scientists (Source: Nursing in Practice)...
POSTED 02/10/2010 at 08:50 AM --
|
Cancer study "could help thousands"
The discovery of certain genetic faults could help experts tailor treatment for bowel cancer patients in the future (Source: Pharmacy Europe)...
POSTED 02/10/2010 at 08:09 AM --
|
Bowel cancer study could lead to personalised treatment
A new genetic study has taken scientists a step closer to being able to offer personalised cancer treatment. (Source: Nursing Times Breaking News)...
POSTED 02/10/2010 at 05:39 AM --
|
Guidance for public health and commissioners: bowel cancer screening programme
The objectives of the programme are to: identify and invite eligible men and women for screening, provide clear information quickly to people with either normal or abnormal faecal occult blood test (FOBt) results, diagnose a significant proportion of cancers at an early stage, minimise anxiety among participants in the programme, make the best use of screening resources, develop the staff who deliver the screening service, and to continue research into screening for diagnosis and treatment of colorectal cancer. Intended audience: Public health leads and commissioners in primary care trusts (PCTs). Publication history information: Published February 2008. Access: Available to the general public. (Source: Gastroenterology and Liver Diseases Specialist Library - Prevention)...
POSTED 02/08/2010 at 05:23 AM --
|
Guidance for public health and commissioners: bowel cancer screening programme
The objectives of the programme are to: identify and invite eligible men and women for screening, provide clear information quickly to people with either normal or abnormal faecal occult blood test (FOBt) results, diagnose a significant proportion of cancers at an early stage, minimise anxiety among participants in the programme, make the best use of screening resources, develop the staff who deliver the screening service, and to continue research into screening for diagnosis and treatment of colorectal cancer. Intended audience: Public health leads and commissioners in primary care trusts (PCTs). Publication history information: Published February 2008. Access: Available to the general public. (Source: Gastroenterology and Liver Diseases Specialist Library - Colon and rectum)...
POSTED 02/08/2010 at 05:23 AM --
|
Understanding of chemoprophylaxis and concordance in inflammatory bowel disease.
CONCLUSION: Despite good self-reported concordance, half of the patients were unaware of an association between colitis and bowel cancer. Explaining the potential chemoprophylactic benefits may enhance patients' overall concordance to 5-aminosalicylic acid and ursodeoxycholic acid and help maintain remission.
PMID: 20128025 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)...
POSTED 02/04/2010 at 10:10 PM --
|
The simple bowel cancer test that could save your life
For Dianne Smith, believes a speck of blood she had spotted three years previously was the only early symptom of the bowel cancer. (Source: the Mail online | Health)...
POSTED 02/02/2010 at 04:20 AM --
|
Exploratory study examining barriers to participation in colorectal cancer screening.
Conclusion: Bowel cancer screening participation rates are currently lower than those associated with breast and prostate screening. Reducing perceptions of embarrassment and discomfort, increasing awareness of potential health benefits and maximising participation in other screening procedures might increase participation in bowel cancer screening.
PMID: 20136809 [PubMed - in process] (Source: The Australian Journal of Rural Health)...
POSTED 01/31/2010 at 06:00 PM --
|
[Assessment of the quality of bowel cancer surgery: "from the mesorectum to the mesocolon"]
Authors: García-Granero E
PMID: 20116051 [PubMed - as supplied by publisher] (Source: Cirugia eEspanola)...
POSTED 01/26/2010 at 06:00 PM --
|
Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastases
Background
Involvement of hepatic lymph node in patients with colorectal liver metastases is associated with poor prognosis.
Objectives
To determine the benefits and harms of curative liver resection with lymphadenectomy versus other treatments for colorectal liver metastases with hepatic node involvement.
Search strategy
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and LILACS until September 2009 for identifying the randomised trials.
Selection criteria
We considered only randomised clinical trials (irrespective of language, blinding, or publication status) comparing liver resection (alone or in combination with radiofrequency......
POSTED 01/26/2010 at 08:19 AM --
|
Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastases
Background
Involvement of hepatic lymph node in patients with colorectal liver metastases is associated with poor prognosis.
Objectives
To determine the benefits and harms of curative liver resection with lymphadenectomy versus other treatments for colorectal liver metastases with hepatic node involvement.
Search strategy
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and LILACS until September 2009 for identifying the randomised trials.
Selection criteria
We considered only randomised clinical trials (irrespective of language, blinding, or publication status) comparing liver resection (alone or in combination with radiofrequency......
POSTED 01/26/2010 at 07:20 AM --
|
